Programs & products

Innate Pharma SA announced that its partnership with Novo Nordisk A/S is being refocused to the inflammatory field.

Innate Pharma SA announces today the entry into regulatory pre-clinical development of IPH 2301, a novel monoclonal antibody targeting NK (Natural Killer) and T cells. It is the first antibody from...

Innate Pharma SA today announces results for its Phase IIa study with IPH 1101, an agonist of gamma delta T cells, as a second line monotherapy in metastatic renal cell carcinoma. In connection with...

Innate Pharma SA announces today that IPH 1101 in combination with rituximab was authorized to enter the second part of the Phase I/II trial in follicular non-Hodgkin's lymphoma.

Innate Pharma SA announces that it has acquired the worldwide exclusive development and commercial rights to IPH2101 from Novo Nordisk A/S in the context of a swap of products.

Innate Pharma SA announces that the preclinical rationale of the gamma-delta T cell immunotherapy in type-C viral hepatitis was presented today at the AASLD (American Association for the Study of...

Innate Pharma SA announces the entry in pre-clinical validation of a new drug candidate: IPH 4201. IPH 4201 is a monoclonal antibody targeting a specific antigen on pancreatic cancer cells.

Vivalis and Innate Pharma sign a collaboration and commercial license agreement to develop Innate's novel monoclonal antibody, to be manufactured with Vivalis' EB66® platform, for rare cutaneous...

Innate Pharma SA announces the achievement of a milestone payment in a new monoclonal antibody project developed in collaboration with Novo Nordisk A/S.